v3.26.1
Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Segment
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Other Commitments [Line Items]          
Impairment of intangible assets $ 0 $ 0 $ 0 $ 0  
Intangible assets, net 103,448   103,448   $ 108,893
Amortization of intangible assets     $ 5,445 5,444  
Number of reportable segments | Segment     1    
Neuren Pharmaceuticals Limited [Member] | License Agreements [Member]          
Other Commitments [Line Items]          
Finite-Lived Intangible Assets, Amortization Expense, Remainder of 2026 5,400   $ 5,400    
Amortization of intangible assets 2,700 $ 2,700 5,400 $ 5,400  
Finite-Lived Intangible Assets, Amortization Expense, Subsequent year 10,900   10,900    
FDA approval, Sales of DAYBUE and Sale of PRV [Member] | Neuren Pharmaceuticals Limited [Member] | License Agreements [Member]          
Other Commitments [Line Items]          
Intangible assets, net $ 138,800   $ 138,800